| 2.28 0.06 (2.7%) | 05-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.02 | 1-year : | 3.32 |
| Resists | First : | 2.58 | Second : | 2.84 |
| Pivot price | 2.32 | |||
| Supports | First : | 2.16 | Second : | 1.79 |
| MAs | MA(5) : | 2.26  |
MA(20) : | 2.33 |
| MA(100) : | 2.56 |
MA(250) : | 2.24 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 21.9 |
D(3) : | 21.9 |
| RSI | RSI(14): 46 |
|||
| 52-week | High : | 4.05 | Low : | 1.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GDTC ] has closed above bottom band by 30.7%. Bollinger Bands are 68.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.6 - 2.62 | 2.62 - 2.64 |
| Low: | 2.25 - 2.27 | 2.27 - 2.28 |
| Close: | 2.26 - 2.28 | 2.28 - 2.3 |
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Wed, 07 May 2025
CytoMed Therapeutics Reports 2024 Financial Results and Clinical Progress - TipRanks
Wed, 30 Apr 2025
CytoMed Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Tue, 29 Apr 2025
Interview with the Chairman: CytoMed Therapeutics Ltd. (NASDAQ:GDTC) - The Wall Street Transcript
Mon, 28 Apr 2025
CytoMed Therapeutics Reports Full Year Ended December 31, - GlobeNewswire
Mon, 28 Apr 2025
CytoMed Therapeutics Announces 2024 Financial Results and Clinical Advances - TipRanks
Mon, 28 Apr 2025
CytoMed 2024 Results: 39% Lower Losses as Biotech Advances Novel Cancer Cell Therapy Trial - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 70.4 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 77 (K) |
| Shares Short P.Month | 94 (K) |
| EPS | -0.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.77 |
| Profit Margin | 0 % |
| Operating Margin | -530.4 % |
| Return on Assets (ttm) | -17.5 % |
| Return on Equity (ttm) | -24.9 % |
| Qtrly Rev. Growth | 24.8 % |
| Gross Profit (p.s.) | 0.04 |
| Sales Per Share | 0.04 |
| EBITDA (p.s.) | -0.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -13.42 |
| PEG Ratio | 0 |
| Price to Book value | 2.92 |
| Price to Sales | 52.27 |
| Price to Cash Flow | -9.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|